ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

VERV Verve Therapeutics Inc

6.2784
0.2784 (4.64%)
After Hours
Last Updated: 09:15:31
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Verve Therapeutics Inc VERV NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.2784 4.64% 6.2784 09:15:31
Open Price Low Price High Price Close Price Previous Close
6.13 6.00 6.25 6.15 6.00
more quote information »

Recent News

Date Time Source Heading
02/4/202422:00GLOBEVerve Therapeutics Announces Updates on its PCSK9 Program
29/3/202407:51GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
02/3/202408:01GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
28/2/202400:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/2/202400:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202423:45EDGAR2Form 8-K - Current report
27/2/202423:30GLOBEVerve Therapeutics Provides Pipeline Progress and Reports..
17/2/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:30GLOBEVerve Therapeutics to Participate in the Guggenheim..
02/1/202422:30GLOBEVerve Therapeutics to Present at the 42nd Annual J.P. Morgan..
02/12/202308:00GLOBEVerve Therapeutics Announces Closing of Public Offering of..
30/11/202308:54EDGAR2Form 8-K - Current report
30/11/202308:47EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/11/202322:47DJNVerve Therapeutics Shares Tumble Premarket After Stock Sales
29/11/202314:37GLOBEVerve Therapeutics Announces Pricing of Public Offering of..
29/11/202308:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/11/202308:01GLOBEVerve Therapeutics Announces Proposed Public Offering of..
13/11/202322:34EDGAR2Form 8-K - Current report
13/11/202307:30GLOBEVerve Therapeutics Announces Interim Data for VERVE-101..
07/11/202323:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202323:00EDGAR2Form 8-K - Current report
07/11/202322:30GLOBEVerve Therapeutics Highlights Recent Company Progress and..
31/10/202321:59DJNBeam Therapeutics to Sell Rights in Verve Licensing Deal to..
31/10/202321:01GLOBEVerve and Lilly Relationship Expands to Include Verve’s In..
23/10/202322:22DJNVerve Therapeutics Gets Clinical Hold For VERVE-101 Lifted..
23/10/202321:41EDGAR2Form 8-K - Current report
23/10/202321:30GLOBEVerve Therapeutics Announces Clearance of Investigational..
26/9/202320:30GLOBEVerve to Present Interim Data from the heart-1 Phase 1b..
22/9/202306:05GLOBEVerve Therapeutics to Participate in the 2023 Cantor Global..
18/9/202320:30GLOBEVerve Expands Leadership Team with Appointment of Frederick..
10/8/202321:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202321:00EDGAR2Form 8-K - Current report
10/8/202320:30GLOBEVerve Therapeutics Highlights Recent Company Progress and..
03/8/202320:30GLOBEVerve Therapeutics to Present at the Canaccord 43rd Annual..
15/6/202321:16DJNVerve Therapeutics Strikes Gene Editing Deal With Eli Lilly
15/6/202320:30GLOBEVerve Establishes Global Collaboration with Lilly to Advance..
01/6/202320:30GLOBEVerve Therapeutics to Participate in the 2023 Jefferies..
23/5/202320:30GLOBEVerve Therapeutics to Participate in the Stifel 2023..
15/5/202320:30GLOBEVerve Therapeutics Announces Pipeline Progress and Expansion..
09/5/202320:30GLOBEVerve Therapeutics to Participate in the RBC Capital Markets..

Your Recent History

Delayed Upgrade Clock